Mer­ck out­flanks Pfiz­er's 20-va­lent shot with pneu­mo­coc­cal vac­cine ap­proval for kids

Back in April, the FDA asked for more analy­sis from Mer­ck on its 15-va­lent pneu­mo­coc­cal vac­cine for chil­dren and pushed back its ap­proval dead­line by three months. As the three-month mark ap­proach­es, the FDA ap­pears to be sat­is­fied.

Mer­ck an­nounced to­day that the FDA ap­proved its vac­cine for chil­dren ages 6 weeks and up, mak­ing it the third pneu­mo­coc­cal shot ap­proved for chil­dren. The vac­cine, which is mar­ket­ed as Vaxneu­vance, was al­ready OK’d for adults back in Ju­ly 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER